We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+24.59%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.9B
AUM Growth
+$12.2B
(+25%)
Cap. Flow
+$2B
Cap. Flow
% of AUM
3.34%
Top 10 Holdings %
Top 10 Hldgs %
21.63%
Holding
3,213
New
281
Increased
1,628
Reduced
1,147
Closed
147
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$134M |
| 2 |
Microsoft
MSFT
|
+$119M |
| 3 |
Apple
AAPL
|
+$87.6M |
| 4 |
AbbVie
ABBV
|
+$61.7M |
| 5 |
Meta Platforms (Facebook)
META
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$92.9M |
| 2 |
RTN
Raytheon Company
RTN
|
+$71.6M |
| 3 |
CY
Cypress Semiconductor
CY
|
+$23.6M |
| 4 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$12.9M |
| 5 |
Domino's
DPZ
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.43% |
| 2 | Healthcare | 14.28% |
| 3 | Financials | 13.11% |
| 4 | Consumer Discretionary | 10.94% |
| 5 | Communication Services | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Mesa Laboratories
MLAB
$574M
| $2.51M | ﹤0.01% |
11,570
-697
| -6% | -$161K |
|
1602
Moelis & Co
MC
$4.94B
| $2.49M | ﹤0.01% |
80,026
+13,556
| +20% | +$425K |
|
|
RVNC
1603
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.49M | ﹤0.01% |
102,065
+20,597
| +25% | +$407K |
|
1604
Yext
YEXT
$574M
| $2.49M | ﹤0.01% |
149,874
+24,597
| +20% | +$345K |
|
|
DMC
1605
Del Monte Corp
DMC
$1.45B
| $2.48M | ﹤0.01% |
100,840
-8,833
| -8% | -$231K |
|
1606
Cactus
WHD
$5.44B
| $2.48M | ﹤0.01% |
120,248
+15,713
| +15% | +$273K |
|
|
PRO
1607
DELISTED
PROS Holdings
PRO
| $2.47M | ﹤0.01% |
55,689
+9,308
| +20% | +$329K |
|
|
ADVM
1608
DELISTED
Adverum Biotechnologies
ADVM
| $2.47M | ﹤0.01% |
11,837
+3,449
| +41% | +$611K |
|
|
ZGNX
1609
DELISTED
Zogenix, Inc.
ZGNX
| $2.46M | ﹤0.01% |
91,257
+29,081
| +47% | +$802K |
|
1610
Kadant
KAI
$3.99B
| $2.46M | ﹤0.01% |
24,661
+754
| +3% | +$67.1K |
|
1611
Renasant Corp
RNST
$3.91B
| $2.45M | ﹤0.01% |
98,515
+1,110
| +1% | +$26.3K |
|
1612
Opko Health
OPK
$1.02B
| $2.45M | ﹤0.01% |
719,038
+76,646
| +12% | +$172K |
|
|
NGHC
1613
DELISTED
National General Holdings Corp
NGHC
| $2.45M | ﹤0.01% |
113,489
+11,003
| +11% | +$207K |
|
|
PINC
1614
DELISTED
Premier
PINC
| $2.45M | ﹤0.01% |
71,411
+2,265
| +3% | +$74.4K |
|
1615
Amkor Technology
AMKR
$13.7B
| $2.44M | ﹤0.01% |
198,648
+3,872
| +2% | +$40K |
|
|
TWO
1616
Two Harbors Investment
TWO
$1.27B
| $2.44M | ﹤0.01% |
121,176
+51,225
| +73% | +$951K |
|
1617
CEVA Inc
CEVA
$1.08B
| $2.44M | ﹤0.01% |
65,272
-5,301
| -8% | -$170K |
|
|
MINI
1618
DELISTED
Mobile Mini Inc
MINI
| $2.44M | ﹤0.01% |
82,794
-75,666
| -48% | -$2.26M |
|
1619
Tactile Systems Technology
TCMD
$665M
| $2.42M | ﹤0.01% |
58,523
-1,593
| -3% | -$74.6K |
|
|
NTUS
1620
DELISTED
Natus Medical Inc
NTUS
| $2.42M | ﹤0.01% |
111,043
+983
| +0.9% | +$22.5K |
|
1621
WesBanco
WSBC
$4B
| $2.42M | ﹤0.01% |
119,237
-662
| -0.6% | -$14.5K |
|
|
ALTR
1622
DELISTED
Altair Engineering Inc
ALTR
| $2.42M | ﹤0.01% |
60,860
+9,066
| +18% | +$308K |
|
1623
Coeur Mining
CDE
$17.9B
| $2.42M | ﹤0.01% |
475,334
-6,517
| -1% | -$29.7K |
|
1624
Element Solutions
ESI
$9.23B
| $2.41M | ﹤0.01% |
221,725
+4,293
| +2% | +$43.1K |
|
1625
MACOM Technology Solutions
MTSI
$23.7B
| $2.4M | ﹤0.01% |
69,935
-13,891
| -17% | -$406K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, RhumbLine Advisers held 3,213 positions worth $59.9B, up 25% from $47.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers deployed $2B of net new capital in Q2 2020, opening 281 new positions and adding to 1,628 existing holdings. Its largest new stake was Otis Worldwide: 701,378 shares worth $39.9M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was iShares Core S&P Mid-Cap ETF, an estimated $12.9M trimmed.
- RhumbLine Advisers's largest Q2 2020 buy was Otis Worldwide: 701,378 shares worth $39.9M.
- RhumbLine Advisers added most to Amazon in Q2 2020, an estimated $134M increase.
- RhumbLine Advisers's biggest Q2 2020 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $12.9M.
- RhumbLine Advisers fully exited Allergan plc in Q2 2020, selling an estimated $92.9M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $59.9B portfolio in Q2 2020.
- RhumbLine Advisers opened 281 new positions and closed 147 in Q2 2020.
- RhumbLine Advisers's portfolio value rose 25% quarter-over-quarter to $59.9B.
Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.